Format

Send to

Choose Destination
See comment in PubMed Commons below
Int Immunopharmacol. 2003 Oct;3(10-11):1557-62.

Protective activity of Lentinan in experimental tuberculosis.

Author information

1
Department of Pathogenic Bacteria, Institute of Microbiology, Bulgarian Academy of Sciences, 26 G. Bonchev St., 1113 Sofia, Bulgaria. semahead@geobiz.net

Abstract

Protective effects of Lentinan (Ajinomoto, Japan) against Mycobacterium tuberculosis infection were studied by in vitro and in vivo mouse models. The effectiveness of Lentinan administrated intraperitoneally (i.p.) before infection at a dose of 1 mg/kg three times at 2-day intervals was monitored in vivo by several parameters (body temperature; spleen weight; CFU counts of M. tuberculosis in spleen, liver and lung; and histomorphological observations). Peritoneal macrophages obtained from animals treated with Lentinan were greatly stimulated, as assayed by establishing their number, acid phosphatase activity, H2O2 production and killing ability against M. tuberculosis in vitro. The in vivo model demonstrated that administration of Lentinan before infection can mobilize host defense potential and reduce mycobacterial infection.

PMID:
12946453
DOI:
10.1016/S1567-5769(03)00178-4
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center